Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Firms Model Ensuring Import Safety; China’s Inconsistencies Worry FDA

This article was originally published in The Tan Sheet

Executive Summary

Firms using Chinese imports to make dietary supplements and other products can look to drug firms for lessons on ensuring the safety of raw materials from China, where adherence to food and drug production regulations remains inconsistent, current and former FDA executives tell a Senate panel
Advertisement

Related Content

NPA China ingredient program
China Bans Using DEG In Toothpaste, But Denies Possible Health Problem
Dingell Says Lab Closures “Frightening,” FDA District Chief Expects Problems
Congress Pushes Food Safety Pact With China As FDA Lauds European Deal
A “Waking Giant” In Food Safety? Experts Discuss China’s Future Of Reform

Topics

Advertisement
UsernamePublicRestriction

Register

PS100748

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel